Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06951672 · ClinicalTrials.gov registry record · NA
AMEND TS Early Feasibility Study
A NA study of Symptomatic Functional MR 3 or Greater, sponsored by Valcare Medical.
- Recruiting
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 11
- Study locations
NCT06951672: Recruiting NA study of Symptomatic Functional MR 3 or Greater, sponsored by Valcare Medical.
NCT06951672 is a NA study of Symptomatic Functional MR 3 or Greater that is actively recruiting participants, run by Valcare Medical. The registered enrollment target is 15 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06951672, a NA study of Symptomatic Functional MR 3 or Greater, is actively recruiting participants, sponsored by Valcare Medical.
- RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 11
- Study locations
Study Summary
Valcare Medical AMEND Trans-Septal System is a mitral valve repair annuloplasty ring implanted in a trans-catheter method intended for correction of mitral regurgitation. It is designed to be used as standalone therapy or in combination with other repair treatments.
Primary Outcome
The definitions of the SAEs are based on the recommendation of the Mitral Valve Academic Research Consortium (MVARC) (Stone, 2015).
Conditions Studied
Interventions
- DEVICE This study will evaluate the safety and functionality of the AMEND™ Trans-Septal System for annuloplasty as a therapy for mitral regurgitation.
Study Locations (11)
New York
- Columbia University Medical Center (CUMC) - New York
- Montefiore Medical Center - The Bronx
Texas
- University of Texas Health Science Center (UTH) - Houston
- Methodist Hospital HCA - San Antonio
Arizona
- Banner University Medical Center - Phoenix - Phoenix
California
- Scripps Health - La Jolla
Georgia
- Piedmont Healthcare - Atlanta
Indiana
- Ascension St. Vincent - Indianapolis
Oregon
- Oregon Health & Science University (OHSU) - Portland
Tennessee
- Saint Thomas Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-09-11 |
| Est. Completion | 2027-04 |
| Phase | NA |
What NCT06951672 shows while recruiting
NCT06951672 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Symptomatic Functional MR 3 or Greater appearing as the primary indexed condition, and to 1 intervention - of which This study will evaluate the safety and functionality of the AMEND™ Trans-Septal System for annuloplasty as a therapy for mitral regurgitation. is the first listed.
NCT06951672 lists 11 locations in 9 states (New York, Texas, Arizona).
Frequently Asked Questions
What is clinical trial NCT06951672 about?
NCT06951672 is a clinical study titled "AMEND TS Early Feasibility Study". Valcare Medical AMEND Trans-Septal System is a mitral valve repair annuloplasty ring implanted in a trans-catheter method intended for correction of mitral regurgitation. It is designed to be used as standalone therapy or in combination with other repair treatments.
What is the current status of trial NCT06951672?
This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2025-09-11. Estimated completion is 2027-04.
What conditions does trial NCT06951672 study?
This clinical trial studies the following conditions: Symptomatic Functional MR 3 or Greater.
What interventions are being tested in trial NCT06951672?
The interventions under investigation include: This study will evaluate the safety and functionality of the AMEND™ Trans-Septal System for annuloplasty as a therapy for mitral regurgitation. (DEVICE).
Who is sponsoring clinical trial NCT06951672?
This trial is sponsored by Valcare Medical, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06951672 being conducted?
This trial has 11 study locations across Arizona, California, Georgia, Indiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06951672's enrollment target sits among peer trials
15 1882nd of 2000 higher than 92 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI